Search results
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 3 days agoAML is a cancer of the blood and bone marrow and is the most common type of acute leukemia in adults. SENTI-202, a potential first-in-class Logic Gated ...
ExxonMobil Hit with $725M Verdict for Failure to Warn About Cancer-Causing Benzene in Gasoline
Morningstar· 6 days agoA Philadelphia jury has returned a $725.5 million verdict against ExxonMobil, finding the company's failure to warn about known health risks of exposure to cancer-causing benzene in its petroleum ...
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress - Innate Pharma (NASDAQ:IPHA)
Benzinga· 2 days agoTwo abstracts on SAR443579 (IPH6101), ANKET® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under development by partner Sanofi in blood cancer Two abstracts on IPH6501, Innate's
Brookfield cancer patient gets ‘a second chance on life’ with stem cells from a Canadian athlete
The News-Times· 2 days agoSubmission of a sample to a national donor program sparked an unexpected connection between a...
Vor Biopharma’s (VOR) Market Outperform Rating Reiterated at JMP Securities
ETF DAILY NEWS· 16 hours agoJMP Securities reiterated their market outperform rating on shares of Vor Biopharma (NYSE:VOR – Free Report) in a research report released on Monday, Benzinga reports. They currently have a ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 21 hours agoPreliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 3 days agoHONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-306
Syros Pharmaceuticals (SYRS) Set to Announce Quarterly Earnings on Tuesday
ETF DAILY NEWS· 5 days agoSyros Pharmaceuticals (NASDAQ:SYRS – Get Free Report) is scheduled to release its earnings data before the market opens on Tuesday, May 14th. Analysts expect Syros Pharmaceuticals to post earnings ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 2 days ago– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML patients to hematopoietic cell transplantation – – SL
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
Digital Journal· 2 days agoRecent news from the Company's two clinical programs includes: A heavily pretreated breast cancer patient, enrolled in the ALG...its upcoming dose optimization trial in 2Q ...